


AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

ASCO21 Virtual Scientific Program
June 4-8, 2021

eCompendium

Copies of files obtained through links contained in this compendium are for personal use only and may not be reproduced without permission from ASCO® and the author of the presentation. This compilation of QR codes is intended as an educational resource and is for the exchange of scientific data to clinical investigators and health care professionals.

Copyright © 2021 Merck Sharp & Dohme Corp., a subsidiary of **Merck & Co., Inc.** All rights reserved.



PEMBROLIZUMAB

Melanoma

Lung

Bladder

RCC

Prostate

Gynecologic

Head and Neck

GI/Gastric

Colorectal

Hepatobiliary

Across Tumor Types

PEMBROLIZUMAB + LENVATINIB

Colorectal

Gastric

Melanoma

RCC

Gynecologic

Hepatobiliary

Translational

BELZUTIFAN
(MK-6482)

RCC

PEMBROLIZUMAB +
OLAPARIB

Lung

FAVEZELIMAB
(MK-4280)

Colorectal

LENVATINIB

Hepatobiliary

OLAPARIB

Prostate

Ovarian

TUCATINIB

Breast




Solid Tumor

SELUMETINIB

Neurofibromatosis







Melanoma

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-mg/KEYNOTE-054 phase 3 trial, pembrolizumab vs placebo after complete resection of high-risk stage III melanoma</p> <p>Eggermont AMM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, van Akkooi A, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suci S, Robert C</p>	Oral Presentation	Sunday June 6, 2021 8:00-11:00 AM		
<p>KEYNOTE-555 Cohort B: Efficacy, safety, and pharmacokinetics of pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma</p> <p>Jacobs C, Rapoport B, Chan SW, Ruff P, Arance Fernandez A, Eizmendi KM, Anderson JR, Lala M, Jain L, Akala O, Chartash E, Cohen G</p>	Poster	Friday June 4, 2021 9:00 AM		








Lung

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage III NSCLC</p> <p>Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Alawin I, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli J-B, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M</p>	Poster Discussion	Friday June 4, 2021 8:00-11:00 AM		
<p>Health-related quality of life for pembrolizumab + ipilimumab vs pembrolizumab + placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score \geq50%: KEYNOTE-598</p> <p>Şendur MAN, Reck M, Rodríguez-Abreu D, Park K, Lee DH, Cicin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B, Hsia T-C, Otterson G, Xu L, Burke T, Samkari A, Boyer M</p>	Poster	Friday June 4, 2021 9:00 AM		






Bladder

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>First-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial cancer: Response and survival results up to 5 years from the KEYNOTE-052 phase 2 study</p> <p>O'Donnell PH, Balar AV, Vuky J, Castellano DE, Bellmunt J, Powles T, Bajorin DF, Grivas P, Hahn NM, Plimack ER, Xu JZ, Godwin JL, Homet Moreno B, de Wit R</p>	Oral Presentation	Monday June 7, 2021 8:00-11:00 AM		
<p>Pembrolizumab vs investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer: 5-year follow-up from the phase 3 KEYNOTE-045 trial</p> <p>Bellmunt J, Necchi N, de Wit R, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Xu J, Homet Moreno B, Godwin JL, Bajorin DF, Vaughn DJ, Fradet Y</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>KEYNOTE-B15/EV-304: A phase 3, randomized, open-label study of perioperative enfortumab vedotin plus pembrolizumab vs chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer</p> <p>Hoimes C, Bedke J, Loriot Y, Nishiyama H, Fang X, Kataria RS, Homet Moreno B, Galsky MD</p>	Poster	Friday June 4, 2021 9:00 AM		






RCC

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Pembrolizumab plus axitinib vs sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: Results from 42-month follow-up of KEYNOTE-426</p> <p>Rini BI, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, Nosov D, Melichar B, Soulières D, Borchiellini D, Vynnychenko I, McDermott RS, Azevedo SJ, Tamada S, Kryzhanivska A, Li C, Burgents JE, Molife LR, Bedke J, Powles T</p>	Oral Presentation	Monday June 7, 2021 8:00-11:00 AM		
<p>A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (Substudy03A)</p> <p>Plimack ER, Hammers HJ, Choueiri TK, Rini BI, Motzer RJ, Suttner L, Perini RF, Willemann-Rogerio J, Albiges L</p>	Poster	Friday June 4, 2021 9:00 AM		





RCC

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Pembrolizumab vs placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study</p> <p>Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, Hajek J, Symeonides S, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas N, Sawrycki P, Perini RF, Zhang P, Willemann-Rogerio J, Imai K, Quinn D, Powles T, on behalf of the KEYNOTE-564 investigators</p>	Plenary Session	Sunday June 6, 2021 1:00 PM		
<p>Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following initial nephrectomy</p> <p>Haas NB, Song Y, Willemann Rogerio J, Zhang S, Adejoro O, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M</p>	Poster	Friday June 4, 2021 9:00 AM		



Prostate

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Pembrolizumab plus enzalutamide for enzalutamide-resistant, metastatic castration-resistant prostate cancer: Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study</p> <p>Graff JN, Tagawa ST, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Kilari D, Ferrario C, Uemura H, Niu C, Poehlein CH, de Wit R, Schloss C, de Bono JS, Antonarakis ES</p>	Poster	Friday June 4, 2021 9:00 AM		





Gynecologic

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer</p> <p>Van Gorp T, Mirza MR, Lortholary A, Cibula D, Walther A, Savarese A, Barretina-Ginesta M-P, Ortaç F, Papadimitriou C, Bodnar L, Lai C-H, Korach J, Marth C, Hasegawa K, Xie X, Barber EL, Coleman RL, Keefe S, Orlowski R, Slomovitz B</p>	<p>Poster</p>	<p>Friday June 4, 2021 9:00 AM</p>		






Head and Neck

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>KEYNOTE-629: Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma</p> <p>Bratland Å, Munoz-Couselo E, Mortier L, Roshdy O, González R, Schachter J, Arance AM, Grange F, Meyer N, Joshi AJ, Billan S, Hughes BGM, Grob JJ, Ramakrishnan K, Zhang P, Gumuscu B, Swaby RF, Gutzmer R</p>	Poster	Friday June 4, 2021 9:00 AM		




GI/Gastric

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>First-line pembrolizumab plus chemotherapy vs chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590</p> <p>Li Z, Sun Y, Ye F, Ma D, Yin X, Zhuang W, Yuan X, Qin S, Zhang Y, Gu K, Zhao K, Xiao J, Cheng Y, Bai Y, Luo S, Wang L, Wang C, Cui Y, Mei L, Shen L</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: Initial findings of the global phase 3 KEYNOTE-811 study</p> <p>Janjigian YY, Kawazoe A, Yañez P, Luo S, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shih C-S, Bhagia P, Chung HC, on behalf of the KEYNOTE-811 investigators</p>	Poster Discussion	Friday June 4, 2021 9:00-10:00 AM		





Colorectal

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Final overall survival for the phase 3 KN177 study: Pembrolizumab vs chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)</p> <p>André T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Zhong W, Fogelman D, Marinello P, Diaz Jr LA</p>	<p>Oral Presentation</p>	<p>Monday June 7, 2021 1:15-4:15 PM</p>		







Hepatobiliary

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study</p> <p>Van Laethem JL, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer D, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Siegel AB, Chisamore M, Wang A, Zhu AX</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study</p> <p>Finn RS, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B, Zhu AX, Breder V, Lim HY, Ogasawara S, Siegel AB, Rahman A, Wei Z, Merle P</p>	Poster	Friday June 4, 2021 9:00 AM		




Across Tumor Types

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Pembrolizumab in microsatellite instability high/mismatch repair-deficient cancers: Updated analysis from phase 2 KEYNOTE-158 study</p> <p>Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Mendonca Bariani G, De Jesus Acosta A, Doi T, Longo Muñoz F, Miller Jr WH, Oh D-Y, Gottfried M, Wang R, Jin F, Norwood K, Marabelle A</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>A comprehensive literature review and meta-analysis on prevalence of BRCAm, HRRm, and HRD+ across tumor types</p> <p>Shao C, Wan J, Tang H, Marley A, Miller C, Brown M, Song Y, Han J, Adeboyege G</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>A comprehensive literature review and meta-analysis on prognostic value of BRCAm, HRRm, and HRD+ across tumor types</p> <p>Shao C, Marley A, Tang H, Wan J, Miller C, Brown M, Song Y, Han J, Adeboyeje G</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Pembrolizumab patient-reported benefits: A perspective based on multiple tumors</p> <p>Wu E, Miskala PH, Siddiqui MK, Rai P, Hajdukova E, Erpelding N, Vanderpuye-Orgle J</p>	Poster	Friday June 4, 2021 9:00 AM		




CRC

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the colorectal cancer cohort</p> <p>Gomez-Roca C, Yanez E, Im S-A, Castanon E, Senellart H, Doherty M, Garcia Corbacho J, Lopez J, Basu B, Maurice-Dror C, Gill S, Ghorri R, Kubiak P, Jin F, Norwood K, Chung HC</p>	Poster	Friday June 4, 2021 9:00 AM		



Colorectal

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort</p> <p>Chung HC, Lwin Z, Gomez-Roca C, Longo Muñoz F, Yanez E, Castanon E, Graham DM, Doherty M, Cassier P, Lopez J, Basu B, Hendifar AE, Maurice-Dror C, Gill S, Ghori R, Kubiak P, Jin F, Norwood K, Saada-Bouزيد E</p>	Poster	Friday June 4, 2021 9:00 AM		



Hepatobiliary

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study</p> <p>Villanueva L, Lwin Z, Chung HC, Gomez-Roca C, Longo Muñoz F, Yanez E, Senellart H, Doherty M, Garcia-Corbacho J, Hendifar AE, Maurice-Dror C, Gill S, Kim TW, Heudobler D, Penel N, Ghorri R, Kubiak P, Jin F, Norwood K, Graham DM</p>	Poster	Friday June 4, 2021 9:00 AM		






Melanoma

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Lenvatinib plus pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004</p> <p>Arance A, de la Cruz Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Marquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Smith AD, Chen K, Diede SJ, Krepler C, Long GV</p>	Oral Presentation	Sunday June 6, 2021 8:00-11:00 AM		





RCC

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Health-related quality-of-life analysis from the phase 3 CLEAR trial of lenvatinib plus pembrolizumab or everolimus vs sunitinib for patients with advanced renal cell carcinoma</p> <p>Motzer R, Porta C, Alekseev B, Young Rha S, Choueiri T, Mendez-Vidal MJ, Hong S-H, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Asfaw AA, He CS, Mody K, Cella D</p>	Oral Presentation	Monday June 7, 2021 8:00-11:00 AM		
<p>KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal carcinoma</p> <p>Lee C-H, Li C, Perini RF, Hoehn D, Albiges L</p>	Poster	Friday June 4, 2021 9:00 AM		






RCC

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Analysis of the CLEAR study in patients with advanced renal cell carcinoma: depth of response and efficacy for selected subgroups in the lenvatinib-plus-pembrolizumab and sunitinib treatment arms</p> <p>Grunwald V, Powles T, Kopyltsov E, Kozlov V, Alonso Gordo TA, Eto M, Hutson T, Motzer R, Winqvist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F, Oya M, Rodriguez-Lopez K, Saito K, Smith A, Porta C</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Post hoc analysis of the CLEAR study in advanced renal cell carcinoma: effect of subsequent therapy on survival outcomes in the lenvatinib + everolimus versus sunitinib treatment arms</p> <p>Hutson T, Choueiri TK, Motzer R, Young Rha S, Alyasova A, Merchan J, Gurney H, Peer A, Takagi T, Porta C, Powles T, Grunwald V, De Giorgi U, Vaishampayan U, Schmidinger M, Glen H, Rodriguez-Lopez K, Xing D, Dutta L, Eto M</p>	Poster	Friday June 4, 2021 9:00 AM		





Gynecologic

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Health-related quality of life in advanced endometrial cancer patients treated with lenvatinib + pembrolizumab or treatment of physician’s choice</p> <p>Lorusso D, Colombo N, Casado Herraез A, Santin A, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay SE, Ray-Coquard IL, Shapira-Frommer R, Man Kim Y, McCormack M, Bird S, Prabhu VS, Nguyen AM, Zhao Q, Dutta L, Makker V</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Treatment patterns and outcomes among patients with microsatellite stable (MSS) advanced endometrial cancer who progressed following previous systemic therapy in the United States: Endometrial cancer health outcomes (ECHO) retrospective chart review study</p> <p>Corman S, Kelkar SS, Odak S, Zhang J, Prabhu VS, Rusibamayila N, Macahilig C, Duska L</p>	Poster	Friday June 4, 2021 9:00 AM		





Translational

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Exploratory circulating biomarker analyses: Lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC)</p> <p>Zhu AX, Llovet JM, Kobayashi M, Ikeda M, Pracht M, Sung MW, Baron AD, Kudo M, Meyer T, Okusaka T, Kumada H, Kaneko S, Hoshi T, Saito K, Li SD, Funahashi Y, Minoshima Y, Dubrovsky L, Finn RS</p>	Poster	Friday June 4, 2021 9:00 AM		





RCC

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α inhibitor, for Von Hippel-Lindau disease-associated clear cell renal cell carcinoma</p> <p>Srinivasan R, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Roy A, Liu Y, Perini RF, Linehan WM, Jonasch E</p>	Poster	Friday June 4, 2021 9:00 AM		



Lung

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib vs concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small-cell lung cancer: KEYLYNK-012</p> <p>Jabbour SK, Cho BC, Bria E, Kato T, Bhosle J, Gainor JF, Reguart N, Wang L, Morgensztern D, Gurary EB, Ashraf TB, Lara-Guerra H, Reck M</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib vs concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC</p> <p>Rimner A, Lai V, Califano R, Jabbour SK, Faivre-Finn C, Cho BC, Kato T, Yu J, Yu L, Zhao B, Pietanza MC, Byers L</p>	Poster	Friday June 4, 2021 9:00 AM		



Colorectal

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>A phase 1 first-in-human study of the anti-LAG-3 antibody MK-4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer</p> <p>Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im S-A, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Healy J, Falchook GS</p>	Poster	Friday June 4, 2021 9:00 AM		



Hepatobiliary

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>The cost effectiveness of first line lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada</p> <p>Trueman D, Liu Y, Geadah M, Hon N, Sabapathy S, Kamboj L, Li H, Lucero M, Meier G</p>	Poster	Friday June 4, 2021 9:00 AM		






Prostate

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m² every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer</p> <p>Reason T, McCrea C, Hettle R, Ghatge S, Poehlein C, Olmos D</p>	Poster	Friday June 4, 2021 9:00 AM		






Ovarian

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>EFFORT: Efficacy of adavosertib in PARP resistance: A randomized 2-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer</p> <p>Westin SN, Coleman RL, Fellman B, Yuan Y, Sood A, Soliman P, Wright A, Horowitz N, Campos S, Konstantinopoulos P, Levenback C, Gershenson D, Lu K, Bayer V, Tukdi S, Rabbit A, Ottesen L, Godin R, Mills G, Li JF</p>	Oral Presentation	Monday June 7, 2021 8:00-11:00 AM		
<p>Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer patients: Phase IIIb OPINION primary analysis</p> <p>Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Rubio Pérez M, Ledermann J, Davidson R, Blakeley C, Bennett J, Brown J, Škof E</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Overall survival results from the phase II LIGHT study</p> <p>Mathews C, Simpkins F, Cadoo K, Liu Y, Provencher D, McCormick C, EINaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Yu H, Aghajanian C</p>	Poster Discussion	Friday June 4, 2021 9:00 AM		






Breast

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>HER2CLIMB-04: Phase 2 open label trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)</p> <p>Krop I, Ramos J, Zhang C, Hamilton E</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer</p> <p>O'Sullivan CC, Ballman KV, McCall L, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin MJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Partridge AH, Carey LA</p>	Poster	Friday June 4, 2021 9:00 AM		





Breast

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)</p> <p>Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey L, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Zhang C, Winer E</p>	Poster	Friday June 4, 2021 9:00 AM		
<p>Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab, and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer</p> <p>Stringer-Reasor EM, O'Brien BJ, Topletz-Erickson A, White J, Lobbous M, Riley K, Childress J, Lamaster K, Melisko M, Morikawa A, de Groot JF, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin NU, Murthy RK</p>	Poster	Friday June 4, 2021 9:00 AM		



Solid Tumor

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
<p>SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress)</p> <p>Stinchcombe T, Monk BJ, Okines AFC, Pohlmann PR, Yu EY, Bekaii-Saab TS, Nakamura Y, O'Malley DM, Kang V, Walker LN, Reck M</p>	Poster	Friday June 4, 2021 9:00 AM		



Neurofibromatosis

Title/Author	Presentation Type	Date and Time EDT	Download Presentation	Download Poster Slides
Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (US) Yang X, Yoo HK, Amin S, Cheng WY, Sipsma H, Sundaresan S, Zhang L, Duh MS	Poster	Friday June 4, 2021 9:00 AM	